Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REBRAnD trial of TW-012R in PSEN1-mutant Alzheimer's disease
jRCT2041200008Completed
- Sponsor
- Time Therapeutics
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of TW-012R in Alzheimer's disease (AD) (3 arms), sponsored by Time Therapeutics. Primary endpoints: Safety, SIB-J and 1 more. Started Jun 2020; status: completed.
02
Drugs
TW-012R
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2041200008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200008.